Recast 10 mg (Tablet)

Unit Price: ৳ 15.00 (20's pack: ৳ 300.00)

Medicine Details

Category	Details
Generic	Montelukast sodium
Company	Monicopharma ltd
Also available as	Recast 4 mg chewable tablet Recast 5 mg chewable tablet

Prophylaxis and chronic treatment of asthma
Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis

Dosage for adults and adolescents 15 years of age and older: Montelukast 10 mg tablet once daily
Dosage for pediatric patients 6 to 14 years of age: Montelukast 5 mg tablet once daily
Dosage for pediatric patients 2 years to 5 years of age: Montelukast 4 mg tablet once daily
Dosage for pediatric patients 6 months to 5 years of age: Montelukast 4 mg oral granules once daily
No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency
No dosage adjustment is recommended in patients with renal insufficiency
The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of montelukast are similar in elderly and younger adults
The plasma half-life of montelukast is slightly longer in the elderly
The safety and efficacy of Montelukast have been established in pediatric patients with asthma 6 months to 14 years of age

Administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions
Recommended clinical dose of Recast did not have clinically important effects on the pharmacokinetics of certain drugs
Recast was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions
Phenobarbital, which induces hepatic metabolism, decreased the AUC of Recast approximately 40% following a single 10mg dose of Recast
No dosage adjustment for Recast is recommended
Clinical monitoring may be employed when potent cytochrome P450 enzyme inducers are co-administered with Recast

Contraindicated in patients who are hypersensitive to any component of this product

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection
Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders
Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor

Not indicated for use in the reversal of bronchospasm in acute asthma attacks
Appropriate rescue medication should be available
Therapy with Recast can be continued during acute exacerbations of asthma
Dose of inhaled corticosteroid may be reduced gradually under medical supervision
Recast should not be abruptly substituted for inhaled or oral corticosteroids
Not to be used as monotherapy for the treatment and management of exercise induced bronchospasm
Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Recast

Majority of overdosage reports resulted in no adverse experiences
Adverse experiences included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity
Usual supportive measures may be employed in the event of overdose